GUFICBIO
Pharmaceuticals & Drugs
₹328.1
0.00 (0.00%)
| Market Cap | 3,268 Cr | EPS | 8.2 | High | 331.7 | ||
| Stock P/E | 39.7 | Net Profit Margin | 10.8 | Low | 325 |
Performance
Today’s Low
Today’s High
325
331.7
52W Low
52W High
177.65
348.25
| Open Price | 328.4 | Volume | 1 |
| Prev. Close | 326 |
Fundamentals
| Market Cap | 3,268 Cr | ROE | 25.8% | ||
| P/E Ratio(TTM) | 39.7 | EPS(TTM) | 0.0 | ||
| P/B Ratio | 6.7 | Dividend Yield | 0.0% | ||
| Industry P/E | 40.3 | Book Value | 48.9 | ||
| Face Value | 1.0 |
About the Company
The company been in the Pharmaceutical industry since 1970 and is known and respected for Innovative and high Quality pharmaceutical and Herbal Products along with a wide range of APIs.
The company is one of the largest manufacturers of Lyophilized injections in India and has a fully automated lyophilization plant. Its lyophillized product portfolio includes Antibiotic, Antifungal, Cardiac, Infertility, Antiviral and proton-pump inhibitor segments.
The company’s products are supplied to most major hospital chains and leading medical facilities and it has an extensive network of representatives promoting these products all across India.
The company combines its high end Lyophilisation technology with R&D expertise to create differentiated products targeted at domestic and international markets. It has set up one of the largest and state of the art lyophilisation facility with major accreditations like EU-GMP, WHO-GMP, Ukraine-GMP.
Business area of the company
The company is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.
Products of the company
- Pharmaceutical
- Herbal
- API / Bulk Drugs
- Personal care
- International
History and milestone
Past Initiatives
- First Indian to produce Doxycycline Inj.
- First Indian company to make Liquid Oxytetracycline Inj.
- Mox (Amoxicillin) and Zole ointment featured among the top 100 pharma brands
- First Company to launch Boswellia Serrata tablets
- Pioneer in developing Kid tablet in India
- Hived off Mox and Zole to Ranbaxy
2007-2009
- Initiated contract manufacturing
- Commenced international exports
2010-2015
- Received patents for Anidulafungin and Tigecycline lyophilized inj.
- Launched Criticare division
2016
- Set up a full automatic state of the art facility at Navsari, India under the name Gufic Lifesciences Pvt ltd and received EU GMP approval
- Launched Ferticare and Criticare Life divisions
2017-2019
- Received patents for Rifabutin and Micafunginlyophilized inj.
- Exported Vancomycin lyophilized Inj. to Germany
- Manufacturing capacity ramped up to 31 million vials per annum
- Launched Ferticare Life division
2020
- Manufacturing Remdesivir for Hetero
- Increased capacity to 48 million vials per annum
2022
- Incorporated wholly owned subsidiary company namely ‘Gufic UK’
- Received DCGI approval for Thymosin Alpha-1 (Immunocin - A Brand of Gufic for the said drug)
| Parent Organization | Gufic Biosciences Ltd. | Managing Director | Jayesh P Choksi | ||
| Founded | 1984 | NSE Symbol | GUFICBIO |
Financials
All values are in Rs Cr
Shareholding Pattern
Domestic Institutions
1.13%
Foreign Institutions
1.38%
Mutual Funds
1.03%
Promoters
75.00%
Domestic Institutions
1.13%
Foreign Institutions
1.38%
Mutual Funds
1.03%
Promoters
75.00%
Domestic Institutions
1.13%
Foreign Institutions
1.38%
Mutual Funds
1.03%
Promoters
75.00%
Domestic Institutions
1.13%
Foreign Institutions
1.38%
Mutual Funds
1.03%
Promoters
75.00%
Domestic Institutions
1.13%
Foreign Institutions
1.38%
Mutual Funds
1.03%
Promoters
75.00%
Peer Comparison
| Company | 52 Week | Market Price | P/E Ratio | Financials | Share Holding |
|---|---|---|---|---|---|
328.1(0.6%) | 39.7 | ||||
366.65(-1.2%) | 0.0 | ||||
285.2(-1.0%) | 43.4 | ||||
118.1(-0.3%) | 0.0 |
